What were the results of Novo Nordisk's oral GLP-1 drug trial in children?

The oral GLP-1 drug significantly lowered blood sugar levels in children and adolescents with type 2 diabetes, meeting the main goal of the late-stage trial.

When does Novo Nordisk plan to seek regulatory approval for its oral diabetes drug in young patients?

Novo Nordisk plans to apply for regulatory approval in the second half of 2026 for its oral semaglutide drugs in the United States and the European Union.

Why is a new oral diabetes medication needed for young people?

Type 2 diabetes is increasingly diagnosed in younger people, and existing treatments like metformin are not always effective, while insulin carries risks such as low blood sugar and weight gain.

Home / Health / Novo Nordisk Pill Shows Promise for Diabetic Youth

Novo Nordisk Pill Shows Promise for Diabetic Youth

23 Apr

•

Summary

Oral GLP-1 drug significantly lowered blood sugar in children.
Trial met main goal, showing statistically significant results.
Drugmaker plans regulatory approval application in 2026.

Novo Nordisk Pill Shows Promise for Diabetic Youth

A late-stage trial for Novo Nordisk's oral GLP-1 drug has successfully met its main goal. The medication significantly reduced blood sugar levels in children and adolescents diagnosed with type 2 diabetes. This pivotal study involved 132 patients aged 10 to 17 over a 26-week period.

The trial results showed that patients treated with the oral drug experienced an average reduction in blood sugar levels that was 0.83 percentage points greater than those receiving a placebo. This difference was confirmed as statistically significant by the drugmaker.